Country: Malta
Language: English
Source: Medicines Authority
EFAVIRENZ, EMTRICITABINE, TENOFOVIR DISOPROXIL
PharOS – Pharmaceutical Oriented Services Limited Lesvou str. (end), Thesi Loggos, Industrial Zone, 144 52 Metamorfossi Attikis,, Greece
J05AR06
EFAVIRENZ 600 mg EMTRICITABINE 200 mg TENOFOVIR DISOPROXIL 245 mg
FILM-COATED TABLET
EFAVIRENZ 600 mg EMTRICITABINE 200 mg TENOFOVIR DISOPROXIL 245 mg
POM
ANTIVIRALS FOR SYSTEMIC USE
Withdrawn
2017-11-14
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT EFAVIRENZ/ EMTRICITABINE/ TENOFOVIR DISOPROXIL PHAROS 600 MG/200 MG/245 MG FILM-COATED TABLETS Efavirenz/Emtricitabine/Tenofovir disoproxil READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What Efavirenz/ Emtricitabine/ Tenofovir disoproxil PharOS is and what it is used for 2. What you need to know before you take Efavirenz/ Emtricitabine/ Tenofovir disoproxil PharOS 3. How to take Efavirenz/ Emtricitabine/ Tenofovir disoproxil PharOS 4. Possible side effects 5. How to store Efavirenz/ Emtricitabine/ Tenofovir disoproxil PharOS 6. Contents of the pack and other information 1. WHAT EFAVIRENZ/ EMTRICITABINE/ TENOFOVIR DISOPROXIL PHAROS IS AND WHAT IT IS USED FOR EFAVIRENZ/ EMTRICITABINE/ TENOFOVIR DISOPROXIL PHAROS CONTAINS THREE ACTIVE SUBSTANCES that are used to treat human immunodeficiency virus (HIV) infection: - Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) - Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) - Tenofovir is a nucleotide reverse transcriptase inhibitor (NtRTI) Each of these active substances, also known as antiretroviral medicines, work by interfering with an enzyme (reverse transcriptase) that is essential for the virus to multiply. EFAVIRENZ/ EMTRICITABINE/ TENOFOVIR DISOPROXIL PHAROS IS A TREATMENT FOR HUMAN IMMUNODEFICIENCY VIRUS (HIV) infection in adults aged 18 years and over who have previously been treated with other antiretroviral medicines and have their HIV-1 infection under control fo Read the complete document
Page 1 of 56 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Efavirenz/ Emtricitabine/ Tenofovir disoproxil PharOS 600 mg/200 mg/245 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 600 mg of efavirenz, 200 mg of emtricitabine and tenofovir disoproxil succinate equivalent to 245 mg of tenofovir disoproxil. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet. Pink, capsule-shaped film-coated tablets, plain on both sides, with dimensions 11 mm x 22 mm. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Efavirenz/ Emtricitabine/ Tenofovir disoproxil PharOS is a fixed-dose combination of efavirenz, emtricitabine and tenofovir disoproxil. It is indicated for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years and over with virologic suppression to HIV-1 RNA levels of < 50 copies/ml on their current combination antiretroviral therapy for more than three months. Patients must not have experienced virological failure on any prior antiretroviral therapy and must be known not to have harboured virus strains with mutations conferring significant resistance to any of the three components contained in Efavirenz/ Emtricitabine/ Tenofovir disoproxil PharOS prior to initiation of their first antiretroviral treatment regimen (see sections 4.4 and 5.1). The demonstration of the benefit of the fixed-dose combination of efavirenz/emtricitabine/tenofovir disoproxil is primarily based on 48-week data from a clinical study in which patients with stable virologic suppression on a combination antiretroviral therapy changed to the fixed-dose combination of efavirenz/emtricitabine/tenofovir disoproxil (see section 5.1). No data are currently available from clinical studies with the fixed-dose combination of efavirenz/emtricitabine/tenofovir disoproxil in treatment-naïve or in heavily pretreated patients. No data are available to support the combination of efavirenz, emtricitabine and tenofov Read the complete document